Which oral antiviral should be prescribed for an adult with genital herpes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Oral Antiviral Treatment for Genital Herpes

For genital herpes, prescribe acyclovir, valacyclovir, or famciclovir—all three are equally effective, but valacyclovir offers the most convenient dosing with once or twice-daily regimens.

Treatment Approach Based on Clinical Scenario

For Episodic Treatment of Recurrent Outbreaks

When treating an active recurrence, choose one of these regimens 1:

Acyclovir options:

  • 400 mg orally three times daily for 5 days, OR
  • 200 mg orally five times daily for 5 days, OR
  • 800 mg orally twice daily for 5 days

Valacyclovir:

  • 500 mg orally twice daily for 5 days

Famciclovir:

  • 125 mg orally twice daily for 5 days

Key timing consideration: Treatment must be initiated during the prodrome or within 1 day of lesion onset to provide meaningful benefit 1. Provide patients with a prescription they can fill in advance and keep on hand to enable immediate self-initiation at the first sign of symptoms.

For Daily Suppressive Therapy

Suppressive therapy is indicated for patients with frequent recurrences (≥6 episodes per year) and reduces recurrence frequency by ≥75% 1. Choose one of these regimens 1:

Acyclovir:

  • 400 mg orally twice daily

Valacyclovir:

  • 500 mg orally once daily, OR
  • 1,000 mg orally once daily, OR
  • 250 mg orally twice daily

Famciclovir:

  • 250 mg orally twice daily

Important caveat: Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes per year)—use higher doses or twice-daily regimens in these patients 1.

Comparative Effectiveness

While the 1998 CDC guidelines state that valacyclovir and famciclovir are comparable to acyclovir in clinical outcomes 1, more recent head-to-head research suggests valacyclovir may have a slight edge over famciclovir for viral suppression. One 2006 comparative trial found HSV was detected on 1.3% of days with valacyclovir versus 3.2% with famciclovir 2. However, a 2014 Cochrane review found insufficient evidence to definitively rank the three drugs 3.

Practical Prescribing Considerations

Dosing convenience matters for adherence: Valacyclovir and famciclovir offer simpler dosing schedules than acyclovir, which is particularly important for prolonged suppressive therapy 1. Valacyclovir's once-daily option (1,000 mg) provides the most convenient regimen.

Long-term safety: Acyclovir has the longest safety track record with documented efficacy for up to 6 years of continuous use, while valacyclovir and famciclovir data extend to 1 year 1. However, this reflects study duration rather than safety concerns—no clinically significant acyclovir resistance emerges in immunocompetent patients on suppressive therapy 1.

Reassessment strategy: After 1 year of continuous suppressive therapy, discontinue treatment temporarily to reassess the patient's recurrence rate, as frequency naturally decreases over time in many patients 1.

Special Situations

Severe disease requiring hospitalization (disseminated infection, pneumonitis, hepatitis, meningitis, or encephalitis): Use IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days or until clinical resolution 1.

HSV-2 meningitis: For first episode, use acyclovir 10 mg/kg IV every 8 hours until fever and headache resolve, then switch to valacyclovir 1 g three times daily to complete 14 days total. For recurrent HSV-2 meningitis, oral therapy may be used for the entire course 4. Note that valacyclovir 500 mg twice daily is insufficient for CNS penetration and is not recommended for meningitis suppression 4.

Common Pitfalls to Avoid

  • Don't use topical acyclovir—it is substantially less effective than oral therapy 5
  • Don't delay prescribing—provide patients with advance prescriptions for episodic therapy so they can self-initiate treatment immediately when symptoms begin
  • Don't forget counseling—suppressive therapy reduces but does not eliminate asymptomatic viral shedding or transmission risk 1
  • Don't continue indefinitely without reassessment—evaluate need for ongoing suppression after 1 year

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.